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protein kinase A inhibits tumor 
mutator APOBEC3B through 
phosphorylation
tadahiko Matsumoto1, Kotaro shirakawa1, Masaru Yokoyama  2, Hirofumi Fukuda1, 
Anamaria Daniela sarca  1, sukenao Koyabu1, Hiroyuki Yamazaki1, Yasuhiro Kazuma1, 
Hiroyuki Matsui1, Wataru Maruyama1, Kayoko Nagata1, Fumiko tanabe3, 
Masayuki Kobayashi  1, Keisuke shindo1, Ryo Morishita3, Hironori sato2 &  
Akifumi takaori-Kondo  1
APOBEC3B cytidine deaminase (A3B) catalyzes cytosine into uracil in single-strand DNA and induces 
C-to-T mutations in genomic DNA of various types of tumors. Accumulation of APOBEC signature 
mutations is correlated with a worse prognosis for patients with breast cancer or multiple myeloma, 
suggesting that A3B activity might be a cause of the unfavorable DNA mutations and clonal evolution 
in these tumors. Phosphorylation of conserved threonine residues of other cytidine deaminases, 
activation induced deaminase (AID) and APOBEC3G, inhibits their activity. Here we show that protein 
kinase A (PKA) physically binds to A3B and phosphorylates Thr214. In vitro deaminase assays and 
foreign DNA editing assays in cells confirm that phosphomimetic A3B mutants, T214D and T214E, 
completely lose deaminase activity. Molecular dynamics simulation of A3B phosphorylation reveals that 
Thr214 phosphorylation disrupts binding between the phospho-A3B catalytic core and ssDNA. These 
mutants still inhibit retroviral infectivity at least partially, and also retain full anti-retrotransposition 
activity. These results imply that PKA-mediated phosphorylation inhibits A3B mutagenic activity 
without destructing its innate immune functions. Therefore, PKA activation could reduce further 
accumulation of mutations in A3B overexpressing tumors.
The human apolipoprotein B mRNA editing enzyme, catalytic subunit (APOBEC) protein family comprises 11 
DNA and RNA deaminases: activation induced cytidine deaminase (AID), APOBEC1, APOBEC2, APOBEC3A 
to H and APOBEC41. APOBEC deaminases play pivotal roles in multiple cellular phenomena including cancino-
genesis, metabolism, and innate and adaptive immunity2,3. APOBEC proteins deaminate cytosine into uracil, 
resulting in cytosine to thymine mutations in human and viral genomes. AID, A1, A3A, A3C and A3H are single 
cytidine deaminase domain (CDD) proteins with one zinc-coordinating active site, while A3B, A3D, A3F, and 
A3G are double CDD proteins with two zinc-coordinating motifs. AID plays a crucial role in somatic hypermu-
tation and class switch recombination, which enables diversification of immunoglobulin genes in germinal center 
B cells4. Another APOBEC protein, APOBEC3G (A3G), is a potent anti-retroviral host factor against HIV-15–8 
and HTLV-19. A3G is incorporated into budding virions and induces C-to-T transitions in the minus-strand of 
the viral DNA, inhibiting HIV-1 replication.
One of the APOBEC deaminases, APOBEC3B (A3B) has been recently recognized as an intrinsic DNA 
mutator in various types of cancer. Whole genome sequencing demonstrated that A3B contributes to mutation, 
clonal evolution, chemotherapy resistance and poor outcome of several types of cancers, including breast10–15, 
lung11,16,17, urothelial11,16,18, head and neck11,16 and serous ovarian19 cancers. We previously showed that A3B 
induces APOBEC signature mutations in genomic DNA in a cell based model20. Accumulation of APOBEC sig-
nature mutations correlates with a worse prognosis for patients with breast cancer15 or multiple myeloma21–23, 
suggesting that APOBEC induced mutations could affect clonal evolution or genomic instability of cancers, in 
other words, lead to resistance to chemotherapy and malignant transformation. The data so far highlights that 
inhibition of A3B activity could be an attractive therapeutic strategy in A3B expressing cancers.
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Transcriptional regulation of A3B expression has been extensively investigated by several groups, including 
our own. In several types of cancers, canonical24 or non-canonical NF-κB25, b-Myb26 and human polyomavirus 
infection27,28 induce A3B transcription. On the other hand, post-translational regulation of A3B is not yet fully 
elucidated. A simian viral protein, SIV-Vif, was reported to form an E3 ubiquitin ligase complex with cellular pro-
teins, poly-ubiquitinate and degrade A3B29, but, so far, there have been no reports describing post-translational 
modifications of A3B by intrinsic cellular factors.
Post-translational regulation of APOBEC proteins has received considerable attention after APOBEC3G 
(A3G) was originally identified as a target of the viral E3 ubiquitin ligase complex30–32. HIV-Vif forms an ubiqui-
tin ligase complex with cellular proteins Cul5, EloB/C, Rbx1, which binds and degrades A3G in order to promote 
HIV infection. Protein kinase A (PKA)-mediated phosphorylation is a common regulatory mechanism for AID 
and A3G functions. PKA phosphorylates AID at Thr27 and Ser38, the latter necessary for AID and RPA2 binding, 
which promotes class switch recombination33–35. PKA also phosphorylates A3G both at Thr32 and at Thr218. 
Phosphorylation of Thr32 reduces the affinity between A3G and HIV Vif, and renders the former less susceptible 
to Vif-induced degradation36. Phosphorylation of both A3G Thr218 and AID Thr27 suppresses their cytidine 
deaminase (CDA) activity35. PKA-mediated phosphorylation may be a common molecular switch among some 
of the APOBEC family members.
PKA is a prominent serine/threonine kinase, also called cAMP-dependent protein kinase37. In an unstimu-
lated state, PKA resides in the cytoplasm as an inactive heterotetramer holoenzyme, comprised of two catalytic 
subunits and two regulatory subunits. Upon stimuli that elevate the concentration of cAMP in the cytoplasm, 
two cAMP molecules bind to the regulatory subunits and induce a conformational change, which allows the 
catalytic subunits to dissociate and phosphorylate downstream targets, not only in the cytoplasm but also in the 
nucleus38,39. The most common motif in the physiological substrates of PKA is R(R/X)X(S/T)40. We hypothe-
sized that A3B is also a target of PKA and that PKA-mediated phosphorylation serves as an A3B activity control 
mechanism. In this study, we show that PKA physically binds to and phosphorylates Thr214 of A3B and that 
PKA-mediated phosphorylation of this residue inhibits its deaminase activity.
Results
A3B Ser46 and Thr214 are putative PKA phosphorylation sites. Previous studies reported that PKA 
phosphorylates Thr3232, Thr21835 of A3G and Thr2733 of AID, which changes their enzymatic activity or physio-
logical function. We identified Ser46 and Thr214 of A3B within consensus PKA phosphorylation motifs homolo-
gous to AID and A3G (Supplementary Fig. 1). The two amino acids (Ser46 and Thr214) are located in the CDD of 
A3B, similar to known phosphorylation sites of AID and A3G (Fig. 1a). In addition, two phosphorylation predic-
tion tools, NetPhosK1.0 (http://www.cbs.dtu.dk/services/NetPhosK/)41 and ScanSite (http://scansite.mit.edu)42, 
singled out Ser46 and Thr214 of A3B as putative PKA-mediated phosphorylation sites.
PKA physically binds to A3B and directly phosphorylates Thr214. First, we demonstrated 
the physical binding between A3B and PKA catalytic subunit α (PKACA). We expressed C-terminal HA–
tagged A3B (A3B-HA) and N-terminal FLAG-tagged PKACA (FLAG-PKACA) in HEK293T, followed by 
co-immunoprecipitation (Co-IP). FLAG-PKACA co-precipitated with A3B-HA (Fig. 1b). This binding was con-
firmed by reciprocal Co-IP assays (Fig. 1c). We then examined whether PKACA actually phosphorylates A3B in 
the transfected cells. After immunoprecipitating A3B-HA using anti-HA antibodies, we performed immunoblot 
analyses using anti-phospho-PKA substrate (anti-RXXS/T-p) antibodies and detected the phosphorylated A3B 
(Fig. 1d). We further showed that overexpressing the kinase-dead PKACA mutant, K72H43, did not induce A3B 
phosphorylation (Supplementary Fig. 2). These data indicate that PKACA binds to and phosphorylates A3B in 
HEK293T cells.
Next, to investigate which A3B residues are phosphorylated by PKA, we generated alanine substituted mutants 
of the predicted phosphorylated residues, S46A or T214A respectively (Fig. 1a). We transfected HEK293T cells 
with expression vectors for these mutants along with FLAG-PKACA. Immunoblotting with anti-RXXS/T-p anti-
bodies revealed that PKACA phosphorylates wild type (WT) and S46A, but not T214A A3B-HA (Fig. 1e), sug-
gesting that Thr214 is the PKA phosphorylation site of A3B. Co-IP assays revealed that the A3B T214A mutant 
still binds to PKACA, suggesting that the lack of phosphorylation of T214A mutant is not due to loss of direct 
interaction between T214A and PKA (Supplementary Fig. 3). We purified WT A3B C-terminal domain and its 
mutants (Supplementary Fig. 4) using wheat germ cell free expression system44 to perform in vitro phosphoryl-
ation assays. These assays confirmed that PKACA directly phosphorylates WT A3B-CTD, but not the T214A 
mutant (Fig. 1f).
Phosphomimetic A3B Thr214 mutants lose their cytidine deaminase activity in vitro. According 
to the CDD C-terminal crystal structure, Thr214 participates in the formation of the catalytic pocket45,46 and 
seems to interact with substrate cytosine in single strand DNA (ssDNA) to hold it in an appropriate position47. 
We investigated whether PKA-mediated phosphorylation of this residue affects the molecular function of A3B, 
deamination of cytosine in 5′-TCX sequences of ssDNA. We performed fluorescence resonance energy transfer 
(FRET)-based CDA assays48, using cell lysates with overexpressed WT A3B or its mutants, T214A, T214D and 
T214E (phosphomimetic mutants), and H253R (CDA abrogated mutant) (Fig. 2a), and oligo ssDNA containing 
one target sequence, 5′-TC, with a FAM-TAMRA reporter-quencher pair at its ends. If the substrate oligonu-
cleotide is intact, there is no fluorescence. When A3B catalyzes the deamination of cytosine to uracil, which is 
then excised and the oligonucleotide is cleaved at the remaining abasic site, the quenching effect is lost and flu-
orescence regained (Supplementary Fig. 5a–d)48. With these assays, we show that lysates containing the T214A 
mutant have about one-third of the WT A3B CDA activity, and the phosphomimetic mutants have little to no 
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activity, comparable to that of the empty vector or H253R (Fig. 2b upper panel). The protein levels of A3B or its 
mutants in the lysates are comparable (Fig. 2b, lower panel).
To ascertain that the CDA activity reduction is TC sequence specific, we performed Gel-based CDA assays 
using serially diluted lysates. The initial 43-base long, 5′ FAM-labeled ssDNA (substrate) is subjected to A3B CDA 
activity. The ensuing cytosine to uracil transition, uracil excision and cleavage of the newly formed abasic site lead 
to the formation of a 12-base long, 5′ FAM-labeled oligo DNA (product) (Supplementary Fig. 5e–h). If the sub-
strate is cleaved through a different mechanism, the product length will differ from 12 bases48. As expected, lysates 
containing A3B T214D or T214E lack TC sequence specific CDA activity, similar to that containing A3B H253R 
(Fig. 2c). The lysate of A3B T214A expressing cells preserves this function, albeit weaker than that of A3B WT.
To confirm the changes observed for each mutant, we conducted FRET-based CDA assays using purified 
A3B-CTD and its mutants. T214D and H253R have almost no CDA activity, and T214A has reduced activity 
compared to WT A3B-CTD (Fig. 2d). Using gel-based CDA assays, we confirmed that T214D and H253R lose TC 
sequence specific CDA activity, while T214A preserves only a fraction of the WT A3B activity (Fig. 2e).
We further investigated the CDA activity of in vitro phosphorylated A3B. We incubated purified A3B with 
purified PKACA protein and ATP, and measured the CDA activity of partially phosphorylated A3B using 
FRET-based in vitro CDA assays. The result showed that phosphorylated A3B has reduced CDA activity com-
pared to WT sample (Fig. 2f). Taken together, phosphorylation of Thr214 inhibits A3B CDA activity in vitro.
Figure 1. PKACA phosphorylates A3B Thr214 in vivo and in vitro. (a) Schematic figure of AID, A3G, A3B and 
their mutants. A3B WT CTD and A3B T214A CTD are the purified protein constructs. (b,c) A3B physically 
binds to PKACA. HEK293T cells were transfected with expression vectors for A3B-HA and FLAG-PKACA. 
Lysates from these cells were co-immunoprecipitated with anti-HA (b) or anti-FLAG antibodies (c), followed 
by immunoblot with the indicated antibodies. (d) PKACA phosphorylates A3B in HEK293T cells. HEK293T 
cells were transfected with expression vectors for A3B, A3G, and A3G DM with or without PKACA, as shown 
above. 36hrs after transfection, we semi-purified the APOBECs by immunoprecipitation, and PKA-mediated 
phosphorylation was detected by immunoblot with anti-RXXS/T-p antibodies. (e,f) PKACA phosphorylates 
Thr214 of A3B. (e) Expression vectors for A3B alanine mutants with or without PKACA are introduced in 
HEK293T cells as indicated. 36 hrs after transfection, cells were collected, lysed, immunoprecipitated with 
the anti-HA antibody and subjected to immunoblot with the indicated antibodies. The results show that A3B 
Thr214 is a crucial residue for PKA-mediated phosphorylation. (f) In vitro phosphorylation assays show that 
PKACA directly phosphorylates A3B-CTD, but not A3B T214A CTD. AID, activation-induced deaminase; WT, 
wild type; DM, double mutant; IP, immunoprecipitation.
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A3B phosphomimetic mutants preserve nuclear localization. The subcellular localization of A3B is 
well described12,19,49, and predominantly limited to the nucleus. To assess whether our A3B mutants retain normal, 
steady-state subcellular distribution, we carried out a series of live cell A3B localization studies. We transfected 
HeLa cells with expression vectors for WT or mutants of C-terminal FLAG-tagged A3B, followed by immunofluo-
rescence staining with anti-FLAG antibodies. As previously reported, WT A3B localized exclusively in the nucleus, 
and the T214A, T214D, T214E, and H253R A3B mutants also concentrated in the nucleus (Supplementary Fig. 6). 
These data suggest that PKA mediated phosphorylation does not affect A3B subcellular localization.
Molecular dynamics simulation reckoned that Thr214-phosphorylation and phosphom-
imetic Glu/Asp at 214 induce dissociation of cytosine from the catalytic pocket. To examine 
how phosphorylation or various substitutions of A3B Thr214 influence A3B-ssDNA molecular interactions, 
Figure 2. Phosphomimetic A3B mutants lose their CDA in vitro. (a) Schematic figure of phosphomimetic A3B 
mutants at Thr214. T214D CTD and H253R CTD are the purified protein constructs. (b) Phosphomimetic A3B 
mutants lose their CDA in vitro. FRET-based CDA assays were performed using lysates from HEK293T cells 
with exogenously-expressed A3B or its mutants. Each of the fluorescent intensity numerical values represent the 
average of three independent experiments, normalized to that of the WT sample. Bars indicate standard error 
(SE), and asterisks (*) show statistically significant difference (p < 0.05) (upper panel). The protein levels of the 
A3B mutants used in the experiment were comparable (lower panel). (c) Phosphomimetic A3B mutants lose 
CDA against the TCA sequence in the gel-based CDA assay. In this assay A3B CDA catalyzes substrate 43b oligo 
to 12b oligo transition. Lysates from cells transfected with EV, T214D, T214E or H253R have no CDA, and those 
with T214A have less CDA than those with WT. (d) FRET-based CDA assays using purified proteins. Purified 
C-terminal A3B T214D almost completely loses CDA in vitro. Each of the fluorescent intensity numerical values 
represent the average of three independent experiments. (e) Gel-based CDA assay using purified proteins. A3B 
T214D loses CDA, and T214A has weak CDA against the TCA sequence. (f) Phosphorylation of A3B reduces 
its cytidine deaminase activity. A3B-CTD and T214A-CTD were phosphorylated by PKACA in vitro, and 
subsequently performed in vitro CDA assays. Values represent the average of two independent experiments, and 
bars indicate SE.
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we examined the A3B and ssDNA binding mode using molecular dynamics simulations (MDS). In the WT, 
non-phosphorylated A3B, Zn2+ was surrounded by His253, Glu255, Cys284, and Cys289 in the catalytic pocket 
located in the vicinity of a cytosine of the ssDNA which formed a hydrogen bond with the side chain of Thr214 
(Fig. 3a,b A3B WT). When Thr214 was phosphorylated, the cytosine could not enter the pocket due to the repul-
sion between the negative charges of the phosphate group and ssDNA (Fig. 3b phospho A3B). Similar dissociation 
of the cytosine from the pocket was observed with the phosphomimetic A3B mutants, T214D and T214E (Fig. 3b 
T214D and T214E), and with the T214A mutant, the latter probably due to the lack of hydrogen bond formation 
with the side chain of alanine (Fig. 3b T214A). In contrast, the H253R mutant showed no significant changes in 
the relative positions of the cytosine, Zn2+, and Glu255 in the A3B pocket (Fig. 3b H253R). The results suggest 
that Thr214 also plays an important role in the nucleophilic reaction of A3B-induced cytosine deamination. These 
structural data are well consistent with the phenotypic changes of the A3B variants in the present study.
Phosphomimetic A3B mutants lose foreign DNA editing activity. Cellular A3B is known to possess 
extrinsic DNA, or transfected plasmids, editing activity20. To explore whether A3B phosphorylation alters this 
function, we performed foreign DNA editing assays. DNA from HEK293T cells transfected with expression vec-
tors for WT, T214A, T214D, T214E or H253R A3B-HA mutants along with pEF-UGI and pDON-EGFP as cata-
lytic substrates, was used for differential DNA denaturation PCR (3D-PCR) assays20. 3D-PCR is used to detect the 
amount of C-to-T mutations, based on the rationale that nucleoside alterations from C-G to A-T pairs decrease 
the number of hydrogen bonds within double stranded DNA, lowering its denaturation temperature (Td). As a 
result, DNA containing C-to-T mutations can be amplified at a lower Td compared to mutation-free DNA.
Figure 3. A3B phosphorylation or mutation affects ssDNA binding. Structural models for A3Bs in an ssDNA-
bound state were constructed with reported X-ray crystal structures of A3B (PDB number 5CQH) and ssDNA 
(PDB number 5TD5), and subjected to MDS as described in the experimental procedures section. (a) A 
structure in an ssDNA-bound state at thermodynamic equilibrium, for 80 ns of MDS of the A3B WT-ssDNA 
complex model. The active site of the enzyme is highlighted. A3B residues (T214, H253, E255, C284, and C289), 
located near cytosine and Zn, and presumably involved in the chemical catalysis of DNA cytidine deamination, 
are shown in color sticks. Orange dotted lines indicate hydrogen bonds between Thr214 and cytosine. (b) 
Binding modes of ssDNA with various A3Bs (A3B WT, phosphorylated, T214D, T214E, T214A, and H253R) 
after 80 ns of MDS. A3B active centers around Zn and ssDNA are highlighted.
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Robust EGFP PCR products are obtained at a Td of 88 °C in all samples. In samples containing the EV or 
A3B-HA T214D, T214E, or H253R mutants, there is no relevant amplification at a Td under 88.0 °C. In those con-
taining T214A, PCR products are not detected under 86.3 °C, and samples with WT A3B-HA displayed ampli-
cons as low as 82.2 °C (Fig. 4a). These results suggest that phosphomimetic A3Bs have virtually no foreign DNA 
editing activity, same as the EV or H253R, and the T214A mutant has weaker activity than WT. In these assays, 
the protein levels of the A3B mutants are comparable (Fig. 4b).
To confirm the A3B mediated DNA editing, we sequenced the PCR products obtained at the lowest Td in each 
sample. EGFP sequences are highly edited in the WT A3B-HA sample, with numerous C/G to T/A mutations, 
less so in the T214A sample, while only with residual mutations in the T214D and T214E samples and seemingly 
no or sporadic mutations in the EV and H253R samples (Fig. 4c,d). A3B prefers to deaminate cytosine in a 5′-TC 
sequence, so we looked at the context of C/G to T/A transitions in the hyperedited EGFP sequences. We observed 
a strong bias towards deamination in 5′-TC dinucleotides in WT and T214A samples. These results coincide with 
the in vitro A3B molecular functional changes induced by PKA-mediated phosphorylation described above.
Phosphomimetic A3B mutants retain anti-retroviral activity. Overexpressed A3B inhibits retroviral 
infectivity2. Originally, A3B and other APOBEC3s were thought to inhibit viral infection by inducing mutations 
in the viral genome via their CDA, but catalytically inactive A3B mutants nevertheless retain significant HIV-1 
inhibitory activity8. Therefore, as phosphomimetic A3B mutants also lack CDA activity in cells and in vitro, we 
speculated that they also retain their retroviral inhibitory activity. We performed luciferase-based retroviral infec-
tion assays36. We infected HEK293T cells with reporter viruses containing WT A3B or mutants and measured 
their infectivity as luciferase activity in the cell lysate. WT A3B and the T214A mutant completely blocked HIV 
infectivity, whereas phosphomimetic mutants reduced it by approximately 50% (Fig. 5a). These data indicate that 
phosphomimetic A3B mutants partially retain their anti-retroviral activity.
Phosphomimetic A3B mutants retain LINE1 retrotransposition restriction. A3B inhibits LINE1 
(L1) retrotransposition50 even in the absence of its CDA activity51. To assess whether the phosphomimetic A3Bs 
inhibit L1 retrotransposition as well, we performed GFP-based L1 retrotransposition assays (Fig. 5b). In this 
system, L1 transcription, splicing, reverse transcription, and integration are necessary for EGFP expression, and 
retrotransposition can be monitored as percentage of EGFP positive cells52. EGPF-positivity of HEK293T cells 
transfected with expression vectors for WT A3B or mutants together with the EGFP-based L1 reporter construct, 
Figure 4. Phosphomimetic A3B mutants lose foreign DNA editing activity. (a) 3D-PCR of EGFP exposed to 
WT A3B and its mutants. HEK293T cells were co-transfected with expression vectors for A3B or its mutants 
together with pDON-EGFP and pEF-UGI. Total DNA was recovered 2 days after transfection, and the EGFP 
gene was amplified by 3D-PCR at the indicated denaturation temperatures (Td). (b) Expression levels of A3B 
WT and its mutants were comparable. (c) Mutational matrix of EGFP sequences derived from PCR products 
amplified at the lowest Td in each sample. (d) Dinucleotide context of foreign DNA editing. The rates of C-to-T 
transitions in the indicated dinucleotide sequence are shown.
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was analyzed by flow cytometry after 8 days in culture. We found that L1 retrotransposition occurred in about 5% 
of empty vector-transduced cells. WT A3B reduced retrotransposition 5- to 10-fold; the T214D, T214E, T214A 
and H253R mutants also restrict retrotransposition to similar extents as WT A3B. These data affirm that phos-
phomimetic A3B mutants retain their full anti-retrotransposition activity.
Discussion
In this study, we demonstrate that PKA specifically phosphorylates A3B Thr214 and that PKA-mediated phos-
phorylation of A3B directly suppresses its CDA activity in vitro and in vivo. We also demonstrate that the phos-
phate group on Thr214 forces out cytosine in the substrate ssDNA by electrostatic repulsion. Finally, we prove 
that phosphomimetic A3B mutants lose their mutagenic activity in cells, while retaining their inhibitory activity 
against viral infection and retrotransposition.
We demonstrated that PKA-mediated phosphorylation of Thr214 suppresses its CDA activity in vitro. The ini-
tial FRET-based CDA assays were performed using cell lysates with overexpressed WT or mutant A3Bs, and they 
showed that phosphomimetic A3B mutants have almost no CDA activity. But this did not exclude the possibility 
of other mechanisms inhibiting the in vitro CDA reaction, such as cellular inhibitory factors specifically induced 
by the phosphomimetic A3Bs. We performed FRET-based and gel-based CDA assays using purified A3B-CTD 
WT or mutants, and confirmed that phosphomimetic A3B mutants indeed lost their CDA activities. We also 
quantified the CDA activity of in vitro phosphorylated A3B and found that PKA-induced phosphorylation at 
least partially reduced it. We surmise that our in vitro phosphorylation assays could not phosphorylate all A3B 
proteins, which is why we observed only a partial reduction of CDA activity in these assays.
Figure 5. Phosphomimetic A3B mutants retain anti-retroviral activity and retrotransposition restriction. (a) 
VSV-G pseudotyped NL4-3 viruses were prepared by co-transfection of pNL4-3/Δenv/luc and VSV-G together 
with expression vectors for A3B or its mutants. HEK293T cells were infected with the produced viruses. 
Luciferase activity of the target cell lysate was measured and presented as ratio of infectivity reported to the EV 
(upper panel). Protein levels of A3B and mutants within the lysates or virions are comparable (lower panel) (b) 
A3B suppresses retrotransposition. Both WT and phosphomimetic mutants, and even the catalytically inactive 
H253R mutant, inhibit retrotransposition. Values represent the average of three independent experiments, bars 
indicate SE, and daggers (†) and asterisks (*) show statistically significant difference (p < 0.01 and p < 0.05, 
respectively).
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To gain deeper insight on how PKA-mediated phosphorylation of A3B Thr214 suppresses its CDA activity, we 
performed molecular dynamics simulations (MDS) by computer-generated structural models of A3B WT and its 
mutants to visualize the ssDNA-A3B interaction and determine how it is affected by phosphorylation or muta-
tion of Thr214. According to our data, the additional phosphate group hinders ssDNA entry within the catalytic 
pocket via electrostatic repulsion. The phosphomimetic mutants, T214D and T214E, lead to similar outcomes, 
suggesting that Thr214 phosphorylation inhibits A3B CDA activity by preventing ssDNA docking into its cata-
lytic pocket. The conformational changes displayed by T214A could be explained by the lack of hydrogen bond 
formation between the amino acid and cytosine and support the typical functional alterations of this mutant.
At last, we analyzed whether PKA-mediated phosphorylation of A3B alters its biological functions. To begin 
with, through EGFP-based foreign DNA editing assays and then sequencing, we showed that phosphomimetic 
A3B mutants lose their mutagenic activity, proving that PKA-mediated phosphorylation of A3B also inhibits its 
CDA activity in vivo.
In contrast, phosphomimetic A3Bs have reduced, but still significant inhibitory activity against retroviral 
infection and an anti-retrotransposition activity comparable to that of WT A3B. A3G is a well-known potent 
retroviral infection inhibitory factor and its CDA activity is important for anti-retroviral activity, but catalytically 
inactive A3G also retains a degree of anti-retroviral activity8,53–60 based on reverse transcription suppression. Like 
with A3G, A3B CDA activity contributes to, but is not the only mechanism in HIV-1 restriction3. These reports 
support our data that catalytically inactive phosphomimetic A3B mutants still possess inhibitory activity against 
viral infection. As is the case with the anti-retroviral activity of A3B, Stenglein et al. reported that A3B CDA 
activity is not required to inhibit retrotransposition51 and our data regarding the A3B phosphomimetic mutants is 
consistent with this report. Overall, we show that Thr214 phosphorylated A3B loses its mutagenic activity, while 
it retains its anti-viral and anti-retrotransposition activity in vivo.
Several recent reports identified A3B as an intrinsic mutagen, and mutations induced by A3B are supposed to 
drive clonal evolution and malignant transformation of several types of cancers10,15,21. Therefore, to inhibit A3B 
CDA activity could be an attractive therapeutic strategy to counter A3B-mediated mutagenesis. On the other 
hand, A3B also acts as a potent inhibitory factor against viral infections and retrotranspositions. Furthermore, 
recent studies also reported that transposable elements including LINE-1 or the act of transposition itself were 
responsible for mutations in tumorigenesis61,62. Thus, PKA-mediated phosphorylation might be a better option 
to suppress A3B CDA activity rather than reducing the A3B expression by SIV-Vif or inhibiting the NF-κB 
pathway24,25.
In conclusion, our findings constitute the first evidence that the cytidine deaminase activity of A3B is poten-
tially regulated by PKA-mediated phosphorylation at Thr214. In addition, the phosphomimetic A3B mutants 
retain its anti-viral and anti-retrotransposition functions in vivo. Further studies are required to investigate 
whether phosphorylation of A3B suppresses clonal evolution in particular cancers, including breast cancer and 
myeloma, and whether it improves the outcomes in these cancers.
Experimental Procedures
DNA constructs and cell cultures. pDON-EGFP and pCAG-GS AID, A3G, A3B, A3B H253R and 
H66/253R mutants have been described previously20. The expression vector for Uracil-DNA glycosylase inhibi-
tor, pEF-UGI, was kindly provided by Dr. Reuben S Harris. A3B S46A, T214A, T214D and T214E were generated 
using KOD Fx Neo with primer pairs (S46A: 5′-GAAAATAAAGAGGGGCCGCGCCAATCTCCTTTGGGAC-3′ 
and 5′-GTCCCAAAGGAGATTGGCGCGGCCCCTCTTTATTTTC-3′; T214A: 5′-CTTCGACGGCGCCAGG 
CCTACTTGTGCTATGAG-3′ and 5′-CTCATAGCACAAGTAGGCCTGGCGCCGTCGAAG-3′; T214D: 
5′-CTTCGACGGCGCCAGGACTACTTGTGCTATGAG-3′ and 5′-CTCATAGCACAAGTAGTCCTGGCGCCG 
TCGAAG-3′; T214E: 5′-CTTCGACGGCGCCAGGAGTACTTGTGCTATGAG-3′ and 5′-CTCATAGCAC 
AAGTACTCCTGGCGCCGTCGAAG-3′). The PKACA fragment was PCR amplified from HEK293T cDNA 
using KOD Fx Neo with one pair of primers (5′-NNNNGCATGCATGGGCAACGCCGCCGCCGC-3′ and 
5′-NNNNGGATCCCTAAAACTCAGAAAACTCCTTGCC-3′), and cloned into pcDNA3.1 with Nhe1/BamH1. 
PKACA K72H was generated using KOD Fx Neo with one pair of primers (5′-CCGGGAACCACTATGCC 
ATGCACATCCTCGACAAACAGAAGGTGG-3′ and 5′-CCACCTTCTGTTTGTCGAGGATGTGCATGGCA 
TAGTGGTTCCCGG-3′). HEK293T, HEK293T-eGFP and HeLa cells were maintained with Dulbecco’s Modified 
Eagle’s Medium (Nacalai tesque) containing 10% fetal bovine serum (FBS) and 1% penicillin, streptomycin, and 
glutamine (PSG).
Co-immunoprecipitation assays. HEK293T cells were transfected with expression vectors for A3B-HA or 
its mutants with or without expression vectors for FLAG-PKACA using the XtremeGENE HP DNA Transfection 
Reagent (Roche). At 36 to 48 hours after transfection, cells were lysed with radioimmunoprecipitation (RIPA) 
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% (v/v) Triton X-100, 0.1% (v/v) SDS, 0.1% (v/v) sodium deox-
ycholate, complete Protease Inhibitor Cocktail (Roche), PhosSTOP (Roche)) and immunoprecipitated using 
the Anti-HA (12CA5) antibody (Roche) or the anti-FLAG (M2) antibody (F3165 Sigma-Aldrich) along with 
SureBeads Protein A Magnetic Beads (Bio-Rad) at 4 °C, followed by immunoblotting with anti-HA (12CA5) Ab 
or anti-FLAG (M2) antibodies.
in vivo phosphorylation assays. HEK293T cells were transfected with expression vectors for A3B-HA, 
or its mutants (S46A, or T214A) with or without FLAG-PKACA, or K72H PKACA, using the XtremeGENE 
HP DNA Transfection Reagent. At 36 to 48 hours post transfection, cells were lysed with GST lysis buffer 
(25 mM HEPES-NaOH pH 7.4, 150 mM NaCl, 0.5% (v/v) Triton X-100, 1 mM EDTA, 1 mM MgCl2, 1 mM 
ZnCl2, 10% (v/v) Glycerol, complete Protease Inhibitor Cocktail, PhosSTOP) and immunoprecipitated using the 
Anti-HA (12CA5) antibody (Roche) and Protein G Sepharose 4 Fast Flow at 4 °C, and subsequently analyzed by 
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immunoblotting with anti phospho-PKA substrate rabbit Ab (anti-RXXS/T-p, #9611 Cell Signaling Technology,), 
or Anti-HA (12CA5) antibody (Roche).
in vitro phosphorylation assays. Purified A3B-CTD and its mutants (T214A, T214D, T214E, and H253R) 
were produced using the wheat germ cell-free expression system63,64 and were provided by Cell Free Sciences 
(Supplementary Fig. 4). We incubated 400 ng of A3B-CTD or its mutants along with 200 ng of human recombi-
nant PKACA (C8482 Sigma-Aldrich) in an appropriate buffer (20 mM Tris-HCl pH 7.5, 10 mM MgCl2, 100 ng/
μl BSA, 1 mM DTT, 1 mM ATP, 1 mM cAMP) for 30 minutes at 30 °C, followed by immunoblotting with anti 
Phospho-PKA substrate rabbit Ab and anti-A3B rabbit Ab24.
FRET-based cytidine deaminase assays. We transfected HEK293T cells with expression vectors for A3B 
or its mutants (T214A, T214D, T214E, or H253R) using XtremeGENE HP DNA Transfection Reagent. At 36 to 
48 hours after transfection, cells were lysed with 200 μl of GST lysis buffer/well (6 well plate). 20 μl of each cell 
lysate and 1 pM of single-stranded DNA oligonucleotide (AAATTCAAATAGATAATGTGA) with 5′-attached 
FAM and 3′-attached TAMRA, were incubated with 0.02 units of Uracil DNA Glycosylase (UDG) (NEB) and 
15 μl of reaction buffer (Tris-HCl pH 7.4, 10 mM EDTA) in Nunc 96-well black plates, for 2 hours at 37 °C. In 
this reaction, cytosine was deaminated to uracil, which was excised by UDG, creating an abasic site. This abasic 
site was hydrolytically cleaved in 100 mM NaOH for 30 minutes at 37 °C. We then added 3 μl of 4 M HCl and 
37 μl of 2 M Tris-HCl pH 7.9 per well, and measured the fluorescence intensity using a plate reader (ARVO, 
Perkin-Elmer) with excitation at 485 nm and emission at 535 nm. For the FRET-based CDA assays using purified 
proteins, we used purified WT or mutant A3B instead of lysate, in the indicated amounts. Data shown in Fig. 2b,d 
are obtained from three independent experiments, and in Fig. 2f from two independent experiments. p values 
were calculated by T test, and p < 0.05 was defined as significant difference.
Gel-based CDA assays. 5 μl of lysate with overexpressing A3B WT or mutants and 1 pM of single strand 
DNA oligonucleotide (ATTATTATTATTCAAATGGATTTATTTATTTATTTATTTATTT) with 5′-attached 
FAM were incubated with 0.005 units of UDG and 3.75 μl of reaction buffer in 10 μl reaction volume for 2 hours 
at 37 °C. Subsequently, the oligo products were incubated in 100 mM NaOH for 30 minutes at 37 °C, stained with 
loading dye, and denatured, followed by electrophoresis in 20% Tris/urea-acrylamide gel, which is then visualized 
with the Gel Doc EZ Gel Documentation System (Bio-Rad).
Immunohistochemical analysis. HeLa cells are transfected with expression vectors for WT A3B or its 
mutants and fixed in 4% paraformaldehyde containing PBS. Fixed cells were incubated with anti FLAG M2 anti-
body (Sigma-Aldrich F3165) for 1 hour, following anti-mouse IgG-Alexa Fluor 594 antibody (Abcam, ab150120) 
as secondary antibody for 1 hour and 4′,6-diamidino-2-phenylindole (DAPI). Cells are observed with a fluores-
cence microscope (BZ-9000, KEYENCE).
Foreign DNA editing assays. HEK293T cells were transfected with pDON-EGFP, pEF-UGI, and expres-
sion vectors for A3B WT or its mutants, using the XtremeGENE HP DNA Transfection Reagent. After two-day 
cultures, total DNA was extracted using the Quick Gene DNA whole blood kit (KURABO). First round PCR 
was performed using the primers and rTaq DNA polymerase (Takara), with the following reaction profile: 30 s at 
94 °C, 25 cycles of 30 s at 94 °C, 40 s at 62 °C, and 90 s at 72 °C, followed by 10 min at 72 °C20. The amplicons were 
separated by electrophoresis in 1% (w/v) agarose gel, and extracted with the FastGene Gel/PCR Extraction kit 
(NIPPON Genetics). We used 100 ng of first-round PCR products as templates for nested PCR using KOD Fx Neo 
(TOYOBO), with the following reaction profile: 5 min at 95 °C, 30 cycles of 10 s at 81–88 °C, 30 s at 62 °C, and 60 s 
at 72 °C, followed by 5 min at 72 °C. The amplicons derived at each of the indicated denaturation temperatures 
were then cloned into the pT7-blue vector (Novagen).
Molecular dynamics simulations (MDS). The initial structural model for constructing various monomeric 
A3Bs in an ssDNA-bound state was made by placing the ssDNA in the active center of the A3B mutant at a resolu-
tion of 1.72 Å (PDB number 5TD5)46 into that of the monomeric human A3B at a resolution of 1.73 Å (PDB num-
ber 5CQH)45 by using the tools in the Molecular Operating Environment (MOE) (Chemical Computing Group 
Inc., Montreal, Quebec, Canada). A3B structures with a phosphorylated residue or various single amino acid muta-
tions were constructed with the MOE. MDS were done as described previously65–67. Briefly, the simulations were 
performed by the pmemd.cuda module in the Amber 16 program package68 with the amber ff14SB force field for 
the protein portion69, OL15 force field for the ssDNA70, and the TIP3P water model for simulations of aqueous 
solutions71. The AMBER/DYANA/MOLMOL phosphorylated amino acid library set72 was used for the force field 
of the phosphorylated threonine residue. Bond lengths involving hydrogen were constrained with SHAKE, an 
algorithm to satisfy for Newtonian motion73, and the time step for all MDS was set to 2 fs. A non-bonded cutoff of 
10 Å was used. After calculations for heating up to 310 K for 20 ps using the NVT ensemble for constant volume, 
temperature, and number of particles in the system, simulations were executed using the NPT ensemble for con-
stant pressure, temperature, and number of particles in the system at 1 barr, 310 K, and in 150 mM NaCl for 100 ns.
Luciferase-based retrovirus infection assays. We prepared Luciferase reporter viruses lacking Vif by 
co-transfecting HEK293T cells with pNL43/ΔEnv/ΔVif-Luc plus pVSV-G, together with expression vectors for 
WT A3B, or its mutants. The supernatant was collected at 48 hours and the virus titer measured by p24 ELISA 
(RETROTEK, ZeptoMetrix). HEK293T cells were incubated for 24 hours with adjusted amounts of each virus, 
then lysed in passive lysis buffer (Promega) and checked for luciferase activity (ARVO, Perkin-Elmer). Values 
are the average of three independent experiments, and represented as percentage of the infectivity of the empty 
vector. p values were calculated by T test, and p < 0.05 was defined as significant difference.
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EGFP-based L1 retrotransposition assays. We transfected HEK293T cells with 0.1 μg of the respective 
A3B expression plasmids, 0.5 μg of the EGFP-based L1 reporter vector EF06R, and 0.4 μg of the empty vector. 
Transfected cells were maintained in puromycin (0.5 mg/ml) for 8 days. EGFP expression resulting from ret-
rotransposition was analyzed by flow cytometry. Values are the average of three independent experiments, and 
represented as percentage of the retrotransposition observed in the empty vector sample. p values were calculated 
by T test, and p < 0.05 was defined as significant difference.
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